Regeneron, Sanofi presents results from DISCOVER Phase 4 trial of Dupixent
Confident Investing Starts Here:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
8 hours ago
- Business Wire
Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025. Mehta will lead Bio-Rad's global commercial strategy and execution, succeeding Mike Crowley, who is retiring after a distinguished 26-year career with the company. Mehta brings extensive leadership and commercial expertise in biopharmaceutical, life science research, and diagnostics markets to Bio-Rad. He joins from Labcorp, where he served as Senior Vice President, overseeing large-scale commercial operations for the company's West Division. Prior to Labcorp, Mehta was Vice President and General Manager, Applied Technologies, at Thermo Fisher Scientific. In this role, he successfully managed a global business unit serving diverse markets. Earlier in his career, Mehta held commercial roles of increasing responsibility at Dow Chemical, where he designed and executed impactful commercial growth strategies. He holds an MBA from The Wharton School at the University of Pennsylvania and a BS in Electrical Engineering from Kurkshetra University in Thanesar, India. "Rajat's proven track record in delivering above-market growth, building high-achieving teams, and driving alignment across multiple business segments will be instrumental as we continue to advance our long-term strategy,' said Jon DiVincenzo, Bio-Rad's President and Chief Operating Officer. 'His focus on commercial excellence and deep understanding of large, global organizations spanning both clinical diagnostics and life science markets make him a fantastic addition to our leadership team." Norman Schwartz, Bio-Rad's Chairman and CEO, added, "On behalf of everyone at Bio-Rad, I want to extend our deepest gratitude and acknowledgement to Mike Crowley for his exceptional service and unwavering dedication. Since joining our commercial team in 1998, and particularly during his tenure as EVP of Global Commercial Operations since 2014, Mike's leadership has been instrumental in building our global sales and services organization and contributing to Bio-Rad's overall success.' About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,500 employees, and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit Forward-Looking Statements This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our executive officers. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include risks relating to our international operations; global economic and geopolitical conditions; tariffs or other trade barriers; reductions in government funding or capital spending of our customers; the uncertain pace of the biopharma sector's recovery; international legal and regulatory risks; our ability to develop and market new or improved products; our ability to compete effectively; foreign currency exchange fluctuations; supply chain issues; product quality and liability issues; our ability to integrate acquired companies, products or technologies into our company successfully; changes in the healthcare industry; and natural disasters and other catastrophic events beyond our control. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Yahoo
9 hours ago
- Yahoo
Community Health Workers from Across the Nation Convene in Columbus to Deliberate Public Health's Evolving Landscape at 2025 Unity Conference
Pear Suite to Lead Sessions on Strengthening CHW Partnerships, Streamlining Care, and Unlocking Reimbursement July 28, 2025--(BUSINESS WIRE)--Pear Suite: WHO: The National Association of Community Health Workers (NACHW) will convene its 2025 Unity Conference, bringing together hundreds of Community Health Workers (CHWs) from across the country who all work to bridge healthcare divides and improve outcomes. These frontline public health professionals serve as trusted connectors to care, providing culturally competent, community-based social and health support to historically underserved populations, including low-income families, immigrants and refugees, communities of color, rural residents, individuals with chronic conditions, and people experiencing housing insecurity or behavioral health challenges. Health systems are increasingly recognizing the value of CHWs as essential partners in addressing social drivers of health and improving outcomes upstream. Colby Takeda, NACHW board member, CHW, advocate, and co-founder/CEO of Pear Suite, will headline a key session on navigating the evolving landscape of Medicaid and Medicare reimbursement—and what it means for the future of social and community health care. Under Takeda's leadership, Pear Suite is equipping CHWs nationwide with the tools, technology, and training needed to drive better health outcomes and secure reimbursement for services. WHAT: As healthcare systems grapple with rising costs and persistent disparities, CHWs continue to play a critical role in driving community-level impact. Pear Suite is helping lead this transformation, powering the largest CHW provider network in the U.S. and partnering with over 20 managed care organizations to support more than 11 million Medicaid members across 30+ states. The company's platform also equips thousands of CHWs and hundreds of community-based organizations with tools, technology, and training to expand their impact and access sustainable funding opportunities. This year's event will honor the theme "From Legacy to Leadership: Healing and Transforming Communities Together." The 2025 Unity Conference will bring together CHWs and their allies like Pear Suite for a dynamic, equity-focused program featuring policy discussions, workforce development, research, and cross-sector collaboration. Attendees will be empowered through interactive workshops, certificate-eligible trainings, poster presentations, inspiring keynotes, and a celebratory gala honoring CHW leaders from across the country. WHERE: The 2025 Unity Conference will take place at the Greater Columbus Convention Center. Ohio is home to one of the nation's largest concentrations of CHWs. More than 1,000 registered CHWs work across the state, representing a wide range of sectors and statewide networks. WHEN: The conference will run July 30 – August 1. Pear Suite will present alongside CHW partners and other industry visionaries on the following sessions: "Beyond the Contract: How CBOs and CHWs Partner with Health Plans to Deliver Results" — July 31, 11:00 AM–12:30 PM, featuring Pear Suite Community Engagement Manager Apryl Avila, Head of Partnerships Stefan Savicic, and RIS Foundation CEO Angelica session explores how CHWs can partner with health plans and systems to address social determinants of health and support value-based care. Attendees will gain practical strategies for care coordination, data sharing, and client advocacy—backed by real-world examples of successful integration and impact. "Harnessing Hubs for Health: A CHW-Centered Approach to Care" — August 1st, 10:30am-12pm, featuring Pear Suite head of operations Julia Garcia, Luminar Health founder Bianca De La Luz Paulette, and Everyday Life Consulting CEO Shannon session shows how CHWs can use hub care models to strengthen cross-sector collaboration, streamline referrals, and improve client outcomes. Through insights from CBO leaders, attendees will learn how hubs work and how CHWs can lead and sustain these systems in practice. "Cracking the Code on Medicaid and Medicare Reimbursement for CHWs" — August 1st, 1:30-2:45pm, featuring Pear Suite CEO Colby Takeda, strategic initiatives manager Andrew Linbloom, and Binational of California director of operations Nora Zaragoza- Yáñ hands-on workshop uses real-world case studies to demystify how CHWs can leverage Medicaid and Medicare reimbursement to strengthen program sustainability and impact. Participants will learn which tasks are billable, how to use simple tech tools for documentation, and how policy decisions shape workflows and growth. About Pear Suite Pear Suite is a digital health company that empowers community health workers to address the social determinants of health (SDOH). Through Pear Suite's AI-powered social care navigation platform, health plans, providers, and community-based organizations can boost member engagement, improve health outcomes, and reduce the cost of care in a person-centered, culturally, and linguistically centered way. Pear Suite has supported hundreds of organizations and impacted more than 250,000 lives by driving improvements that are often overlooked in the healthcare landscape. For more information, please visit or follow us on LinkedIn and X. View source version on Contacts Media Contact: SVM Public Relations and Marketing Communicationspearsuite@ / (401)490-9700 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
20 hours ago
- Medscape
WHO Urges Rapid Treatment for Concurrent HIV and Mpox
People living with HIV who contract mpox should start antiretroviral therapy (ART) as soon as possible, according to updated recommendations from the World Health Organization (WHO). People living with HIV are disproportionately infected by mpox and experience more severe disease and higher rates of death than individuals who develop mpox but do not have HIV, said Remco Peters, MD, medical officer of the WHO, who presented the updated guideline at the International AIDS Society Conference on HIV Science. The standard of care calls for initiation of ART within 7 days of an HIV diagnosis, Peters said in his presentation. Some concerns have been raised about the risk for immune reconstitution inflammatory syndrome associated with mpox, but data are limited, Peters said. However, the guideline developers focused on the 'very clear benefits of direct entry to viral therapy in general for people living with HIV,' he said. Without entry to biotherapy, individuals with low CD4 counts in particular (defined as < 200 cells/mm3) are at greater risk for severe disease and death from mpox, and early treatment of HIV is even more important in this population, given the lack of a specific treatment for mpox, Peters said in his presentation. Consequently, the WHO's strong recommendation, based on moderate certainty of evidence, calls for rapid ART initiation in people with HIV and mpox who are ART-naïve or who have had an extended interruption in ART treatment. In practice, this means that early HIV testing should be conducted when patients present with presumptive or confirmed mpox, said Peters in his presentation. Patients should be referred for ART as soon as possible, including an offer of same-day start, with the goal to provide therapy within 7 days, he said. The guideline also states that people already on ART should continue their therapy if they contract mpox, Peters emphasized. For people already on ART but with an undetectable viral load, ART regimens should be continued without interruption or change, while those with detectable viral loads should be managed accordingly, he added. The guidelines for management of mpox align with the WHO's broader guidance for rapid treatment initiation in new cases of HIV, according to the WHO's press release.
